Ashish Rungta, MD
Child & Adolescent Psychiatry · Flint, MINPI 1629464599
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.
Across 34 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$192
- Johnson & Johnson$118
- Otsuka America Pharmaceutical, Inc.$104
- E.r. Squibb & Sons, L.L.C.$102
- Neurocrine Biosciences, Inc.$65
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
- plus $167 from 5 others
What the payments were for
- Food & beverage$811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 6 | $192 |
| Johnson & Johnson | 3 | $118 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 4 | $102 |
| Neurocrine Biosciences, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| AbbVie | 2 | $40 |
| Lundbeck LLC | 2 | $35 |
| Indivior Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
How this compares
$811 in reported general payments places this provider in the 80th percentile of 73 child & adolescent psychiatry providers in Michigan.
See all child & adolescent psychiatry providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 72 | $251,638 |
| IngrezzaValbenazine Tosylate | 11 | $93,953 |
| Abilify MaintenaAripiprazole | 21 | $63,519 |
| Clozapine | 94 | $7,879 |
| QelbreeViloxazine Hcl | 13 | $5,080 |
| Paliperidone ErPaliperidone | 48 | $5,045 |
| Lurasidone Hcl | 35 | $3,966 |
| Haloperidol Decanoate | 60 | $3,409 |
| Divalproex Sodium ErDivalproex Sodium | 92 | $2,600 |
| Olanzapine OdtOlanzapine | 13 | $1,577 |
| Quetiapine Fumarate | 120 | $1,569 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 11 | $1,437 |
| Divalproex Sodium | 44 | $1,052 |
| Olanzapine | 72 | $1,026 |
| Trazodone Hcl | 128 | $1,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $118 | $251,63872 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $65 | $93,95311 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $104 | $63,51921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 child & adolescent psychiatry providers in Michigan.
Other child & adolescent psychiatry in Flint
- Anjum HandooFlint$364
- Erica BettsFlint$148
- Birgit AmannTroy$980K
- David VillanuevaSterling Heights$140K
- Carol Crouch-RossLivonia$24K
- Robert GarciaNorthville$24K
- Gerald SchmukerSpring Lake$11K
- Mohammad JafferanySaginaw$10K
- Sridevi KodaliLivonia$7K
- Viken MatossianHowell$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.